Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anatomic Stage III Breast Cancer AJCC v8

Conditions

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma

Trial Timeline

Feb 5, 2020 → Dec 31, 2023

NCT ID

NCT03554044

About Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin

Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin is a phase 1 stage product being developed by Amgen for Anatomic Stage III Breast Cancer AJCC v8. The current trial status is completed. This product is registered under clinical trial identifier NCT03554044. Target conditions include Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03554044	Phase 1	Completed	Feb 5, 2020	Dec 31, 2023	Anatomic Stage III Breast Cancer AJCC v8

Competing Products

13 competing products in Anatomic Stage III Breast Cancer AJCC v8

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Niraparib Tosylate Monohydrate	Eli Lilly	Phase 1	29
Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib	AstraZeneca	Phase 2	27
Pembrolizumab + Tamoxifen + Vorinostat	Merck	Phase 2	27
Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib	Novartis	Phase 1/2	39
Lutetium Lu 177 Dotatate	Novartis	Phase 2	42
Sacituzumab Govitecan	Gilead Sciences	Phase 2	39
Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen	Pfizer	Phase 2	35
Abexinostat Tosylate + Fulvestrant + Palbociclib	Pfizer	Phase 1	21
Aromatase Inhibition Therapy	Bristol Myers Squibb	Pre-clinical	33
Pelareorep + Retifanlimab	Incyte	Phase 2	36
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody	Imugene	Phase 1	23
Neratinib	Puma Biotechnology	Phase 2	32
Ivermectin + Balstilmab + Pembrolizumab	Agenus	Phase 1/2	29